Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sanofi (SNY) 'Seemingly Committed' to MannKind's (MNKD) Afrezza, RBC Says; 2nd-Half Efforts to Focus on Awareness
June 9, 2015 12:04 PM EDTRBC Capital analyst Adnan Butt weighed in on MannKind (NASDAQ: MNKD) after partner Sanofi's (NYSE: SNY) update at ADA included Afrezza where it highlighted selling efforts will pick up in second-half. While discussion was modest, SNY plans a more direct patient focus in second half, the analyst comments.
Butt said while while they would have appreciated greater focus, given investments and plans for second half, SNY appears committed to Afrezza for now. He said what matters still is: 1) the growth trajectory in prescriptions 2) hurdles getting worked out, 3) whether... More
